Metagenomi Therapeutics (MGX) Treasury Shares (2023 - 2026)
Metagenomi Therapeutics (MGX) posted quarterly Treasury Shares of $37078.0 for Q1 2026, down 91.36% year-over-year from $429072.0 in Q1 2025, and down 39.34% quarter-over-quarter from $61127.0 in Q4 2025.
Metagenomi Therapeutics (MGX) Treasury Shares (2023 - 2026) Analysis & Trends
Metagenomi Therapeutics (MGX) has reported Treasury Shares for 4 consecutive years, with $37078.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Treasury Shares fell 91.36% year-over-year to $37078.0; the TTM figure through Mar 2026 stood at $37078.0 (down 91.36% YoY), while the FY2025 annual figure was $61127.0, down 86.61% from the prior year.
- Treasury Shares slipped to $37078.0 in Q1 2026 per MGX's latest filing, from $61127.0 in the prior quarter.
- Across five years, Treasury Shares topped out at $41.8 million in Q1 2023 and bottomed at $37078.0 in Q1 2026.
- Historically, Treasury Shares has averaged $13.2 million across 4 years, with a median of $593337.0 in 2024.
- Annual changes were most pronounced in 2024 — Treasury Shares tumbled 98.91% — and 2025, when it soared 37.36%.
- Metagenomi Therapeutics' Treasury Shares stood at $41.8 million in 2023, then sank by 98.91% to $456435.0 in 2024, then tumbled by 86.61% to $61127.0 in 2025, then plunged by 39.34% to $37078.0 in 2026.
- Business Quant data shows MGX's Treasury Shares at $37078.0 in Q1 2026, $61127.0 in Q4 2025, and $591646.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 36.40 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 8.96 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 2.72 Mn |
| 10 | Metagenomi Therapeutics | 46.51 Mn | 46.51 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 13,852.00 |
| Jun 30, 2026 | 13,852.00 |
| Mar 31, 2026 | 37,078.00 |
| Mar 31, 2026 | 37,078.00 |
| Dec 31, 2025 | 61,127.00 |
| Dec 31, 2025 | 61,127.00 |
| Sep 30, 2025 | 591,646.00 |
| Sep 30, 2025 | 591,646.00 |
| Jun 30, 2025 | 684,744.00 |
| Jun 30, 2025 | 684,744.00 |
| Mar 31, 2025 | 429,072.00 |
| Mar 31, 2025 | 429,072.00 |
| Dec 31, 2024 | 456,435.00 |
| Dec 31, 2024 | 456,435.00 |
| Sep 30, 2024 | 593,337.00 |
| Sep 30, 2024 | 593,337.00 |
| Jun 30, 2024 | 498,490.00 |
| Jun 30, 2024 | 498,490.00 |
| Mar 31, 2024 | 915,709.00 |
| Mar 31, 2024 | 915,709.00 |